Now showing items 1-2 of 2
A metabolic biosignature of early response to anti-tuberculosis treatment
(BMC Infectious Diseases, 2014)
Background: The successful treatment of tuberculosis (TB) requires long-term multidrug chemotherapy. Clinical trials to evaluate new drugs and regimens for TB treatment are protracted due to the slow clearance of Mycobacterium ...
Utility of urine LAM Biomarker for treatment response monitoring during 8 weeks of MDR-TB treatment at Mulago National Referral Hospital
(Makerere University, 2022-03)
Background: The current methods used in monitoring treatment response among MDR - TB patients have low sensitivity, take long to give results, are expensive and require BSL3 facilities. It is known that MTB LAM as a biomarker ...